Human-Centric Modeling in Metastatic Breast Cancer: Organoids, Organ-on-Chip Systems, and New Approach Methodologies...

Metastatic breast cancer (MBC) remains an overwhelming clinical challenge due to its inherent clonal evolution and the frequent development of drug resistance. A significant hurdle in therapeutic discovery is the reliance on traditional 2D cell cultures and animal models, which often fail to accurately replicate human tumor pathophysiology or predict clinical responses. Consequently, the field of oncology is increasingly exploring a transition towards human-centric research that prioritizes biological data derived directly from patients. Considering the FDA Modernization Act 2.0 and the 2025 FDA Roadmap, frameworks are being established to explore the integration of new approach methodologies (NAMs)-including patient-derived organoids (PDOs) and organ-on-a-chip (OoC) systems-into the drug development pipeline. This review examines how these platforms aim to better simulate the human physiological environment by capturing the complex architecture and microenvironment of the tumor. We further discuss how the integration of these models with Artificial Intelligence (AI), spatial multi-omics, and real-time liquid biopsies is being investigated to enhance the speed and precision of therapeutic testing. While still in the translational phase, emerging evidence suggests that human-centric platforms may eventually support rapid functional drug screening, potentially informing patient treatment responses within clinically relevant timeframes. Strengthening the biological link between the patient and their longitudinal data represents a promising strategy to address the complexities of MBC and improve clinical outcomes. These human-centric platforms preserve patient-specific tumor heterogeneity, recapitulate microenvironmental interactions, and enable functional drug testing under physiologically relevant conditions, thereby improving translational accuracy compared to conventional models.